School of Pharmacy, University of Tasmania, Hobart, 7000, Australia.
Department of Pediatrics, College of Medicine, King Faisal University, 31982, Al-Hofuf, Al-Ahsa, Saudi Arabia.
J Cardiothorac Surg. 2024 Aug 24;19(1):493. doi: 10.1186/s13019-024-03011-3.
PPHN is a common cause of neonatal respiratory failure and is still a serious condition and associated with high mortality.
To compare the demographic variables, clinical characteristics, and treatment outcomes in neonates with PHHN who underwent ECMO and survived compared to neonates with PHHN who underwent ECMO and died.
We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline and searched ProQuest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature for studies on the development of PPHN in neonates who underwent ECMO, published from January 1, 2010 to May 31, 2023, with English language restriction.
Of the 5689 papers that were identified, 134 articles were included in the systematic review. Studies involving 1814 neonates with PPHN who were placed on ECMO were analyzed (1218 survived and 594 died). Neonates in the PPHN group who died had lower proportion of normal spontaneous vaginal delivery (6.4% vs 1.8%; p value > 0.05) and lower Apgar scores at 1 min and 5 min [i.e., low Apgar score: 1.5% vs 0.5%, moderately abnormal Apgar score: 10.3% vs 1.2% and reassuring Apgar score: 4% vs 2.3%; p value = 0.039] compared to those who survived. Neonates who had PPHN and died had higher proportion of medical comorbidities such as omphalocele (0.7% vs 4.7%), systemic hypotension (1% vs 2.5%), infection with Herpes simplex virus (0.4% vs 2.2%) or Bordetella pertussis (0.7% vs 2%); p = 0.042. Neonates with PPHN in the death group were more likely to present due to congenital diaphragmatic hernia (25.5% vs 47.3%), neonatal respiratory distress syndrome (4.2% vs 13.5%), meconium aspiration syndrome (8% vs 12.1%), pneumonia (1.6% vs 8.4%), sepsis (1.5% vs 8.2%) and alveolar capillary dysplasia with misalignment of pulmonary veins (0.1% vs 4.4%); p = 0.019. Neonates with PPHN who died needed a longer median time of mechanical ventilation (15 days, IQR 10 to 27 vs. 10 days, IQR 7 to 28; p = 0.024) and ECMO use (9.2 days, IQR 3.9 to 13.5 vs. 6 days, IQR 3 to 12.5; p = 0.033), and a shorter median duration of hospital stay (23 days, IQR 12.5 to 46 vs. 58.5 days, IQR 28.2 to 60.7; p = 0.000) compared to the neonates with PPHN who survived. ECMO-related complications such as chylothorax (1% vs 2.7%), intracranial bleeding (1.2% vs 1.7%) and catheter-related infections (0% vs 0.3%) were more frequent in the group of neonates with PPHN who died (p = 0.031).
ECMO in the neonates with PPHN who failed supportive cardiorespiratory care and conventional therapies has been successfully utilized with a neonatal survival rate of 67.1%. Mortality in neonates with PPHN who underwent ECMO was highest in cases born via the caesarean delivery mode or neonates who had lower Apgar scores at birth. Fatality rate in neonates with PPHN who underwent ECMO was the highest in patients with higher rate of specific medical comorbidities (omphalocele, systemic hypotension and infection with Herpes simplex virus or Bordetella pertussis) or cases who had PPHN due to higher rate of specific etiologies (congenital diaphragmatic hernia, neonatal respiratory distress syndrome and meconium aspiration syndrome). Neonates with PPHN who died may need a longer time of mechanical ventilation and ECMO use and a shorter duration of hospital stay; and may experience higher frequency of ECMO-related complications (chylothorax, intracranial bleeding and catheter-related infections) in comparison with the neonates with PPHN who survived.
新生儿持续性肺动脉高压(PPHN)是新生儿呼吸衰竭的常见原因,仍然是一种严重的疾病,与高死亡率相关。
比较接受体外膜肺氧合(ECMO)治疗并存活与接受 ECMO 治疗但死亡的患有 PPHN 的新生儿的人口统计学变量、临床特征和治疗结局。
我们遵循系统评价和荟萃分析的首选报告项目(PRISMA)指南,在 2010 年 1 月 1 日至 2023 年 5 月 31 日期间,使用英语语言限制,在 ProQuest、Medline、Embase、PubMed、CINAHL、Wiley 在线图书馆、Scopus 和 Nature 上搜索关于接受 ECMO 治疗的患有 PPHN 的新生儿的 PPHN 发展的研究。
在确定的 5689 篇论文中,有 134 篇文章被纳入系统评价。分析了 1814 名接受 ECMO 治疗的患有 PPHN 的新生儿(1218 例存活,594 例死亡)。在 PPHN 组中死亡的新生儿中,正常自然分娩的比例较低(6.4% vs 1.8%;p 值>0.05),1 分钟和 5 分钟时的 Apgar 评分较低[即低 Apgar 评分:1.5% vs 0.5%,中度异常 Apgar 评分:10.3% vs 1.2%和令人放心的 Apgar 评分:4% vs 2.3%;p 值=0.039]。与存活的新生儿相比,死亡的患有 PPHN 的新生儿更容易出现卵圆孔未闭(0.7% vs 4.7%)、全身低血压(1% vs 2.5%)、单纯疱疹病毒(0.4% vs 2.2%)或百日咳博德特氏菌(0.7% vs 2%)感染等医疗合并症。死亡组中患有 PPHN 的新生儿更有可能因先天性膈疝(25.5% vs 47.3%)、新生儿呼吸窘迫综合征(4.2% vs 13.5%)、胎粪吸入综合征(8% vs 12.1%)、肺炎(1.6% vs 8.4%)、败血症(1.5% vs 8.2%)和肺静脉排列不齐的肺泡毛细血管发育不良(0.1% vs 4.4%)而发病。死亡的患有 PPHN 的新生儿需要更长的中位机械通气时间(15 天,IQR 10 至 27 与 10 天,IQR 7 至 28;p 值=0.024)和 ECMO 使用时间(9.2 天,IQR 3.9 至 13.5 与 6 天,IQR 3 至 12.5;p 值=0.033),以及更短的中位住院时间(23 天,IQR 12.5 至 46 与 58.5 天,IQR 28.2 至 60.7;p 值=0.000),与存活的患有 PPHN 的新生儿相比。与存活的患有 PPHN 的新生儿相比,患有 PPHN 且死亡的新生儿的 ECMO 相关并发症(乳糜胸,1% vs 2.7%;颅内出血,1.2% vs 1.7%;导管相关感染,0% vs 0.3%)更常见(p 值=0.031)。
在接受支持心肺复苏和常规治疗失败的患有 PPHN 的新生儿中,ECMO 的应用已取得成功,新生儿存活率为 67.1%。接受 ECMO 治疗的患有 PPHN 的新生儿死亡率在经剖宫产分娩或出生时 Apgar 评分较低的新生儿中最高。接受 ECMO 治疗的患有 PPHN 的新生儿死亡率在患有更高特定医疗合并症(卵圆孔未闭、全身低血压和单纯疱疹病毒或百日咳博德特氏菌感染)或因更高特定病因(先天性膈疝、新生儿呼吸窘迫综合征和胎粪吸入综合征)而患有 PPHN 的患者中最高。与存活的患有 PPHN 的新生儿相比,死亡的患有 PPHN 的新生儿可能需要更长的机械通气和 ECMO 使用时间,以及更短的住院时间;并且可能经历更高频率的 ECMO 相关并发症(乳糜胸、颅内出血和导管相关感染)。